Eikon Therapeutics

Series ABiotechnologyprivate

Drug discovery company using real-time single-molecule microscopy to unlock previously undruggable targets.

Valuation
$500M
Total Funding
$73M
Stage
Series A
Sector
Biotechnology
Headquarters
Hayward, CA
CEO
Roger Pomerantz
IPO Status
private

Funding History

Round Amount Date
Series A $73M Mar 2021
Seed $18M Nov 2019

Track Eikon Therapeutics IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO โ€” the pre-IPO intelligence platform.

Loading company data...